Home > In process > Measuring health-related quality of life in multiple sclerosis: comparing the acceptability, validity and responsiveness of the EQ-5D-3L and MSIS-8D. > print

001     285816
005     20260402150430.0
024 7 _ |a 10.1007/s11136-026-04229-5
|2 doi
024 7 _ |a pmid:41920450
|2 pmid
024 7 _ |a 0962-9343
|2 ISSN
024 7 _ |a 1573-2649
|2 ISSN
037 _ _ |a DZNE-2026-00352
041 _ _ |a English
082 _ _ |a 100
100 1 _ |a Goodwin, Elizabeth
|0 0000-0003-1351-9170
|b 0
245 _ _ |a Measuring health-related quality of life in multiple sclerosis: comparing the acceptability, validity and responsiveness of the EQ-5D-3L and MSIS-8D.
260 _ _ |a Cham
|c 2026
|b Springer Nature Switzerland AG
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1775134909_16505
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Purpose: Concerns have been raised about the sensitivity and responsiveness of the EQ-5D, one of the most commonly used preference-based health-related quality of life measures, in the context of multiple sclerosis (MS). In response to these concerns, a condition-specific preference-based measure, the Multiple Sclerosis Impact Scale Eight Dimensions (MSIS-8D), was developed. This research aimed to assess the psychometric and distributional properties of the MSIS-8D compared to the EQ-5D-3L, in people with MS. Methods: Analyses were undertaken using data from the UK MS Register. Both measures were compared in terms of acceptability (missing data), distributional properties (health state frequencies, health state density curves and indices), construct validity in relation to disability, mobility, fatigue, anxiety and depression (discriminative and convergent validity, using ANOVA, independent t-tests and Spearman correlations), and responsiveness to symptom onset and relapse (mean change scores, standardised response means, standardised effect sizes, paired t-tests). Results: The MSIS-8D exhibited superior distributional properties, while the EQ-5D-3L showed greater acceptability. Both measures demonstrated excellent construct validity. Neither measure appeared responsive to symptom onset, and only the MSIS-8D met all criteria for responsiveness when people moved from a non-relapse to a relapse state. Conclusion: Although the MSIS-8D appears to offer superior distributional properties and responsiveness compared to the EQ-5D-3L, the responsiveness of both measures in this analysis was limited. This adds weight to existing concerns about the ability of utility measures used in healthcare decision-making to fully capture treatment effects in MS.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a EQ-5D
|2 Other
650 _ 7 |a Economic evaluation
|2 Other
650 _ 7 |a Health-related quality of life
|2 Other
650 _ 7 |a Multiple sclerosis
|2 Other
650 _ 7 |a Preference-based measures
|2 Other
650 _ 7 |a Psychometrics
|2 Other
700 1 _ |a Michalowsky, Bernhard
|0 P:(DE-2719)2810763
|b 1
700 1 _ |a Middleton, Rod
|0 0000-0002-2130-4420
|b 2
700 1 _ |a Hawton, Annie
|0 0000-0002-1336-5899
|b 3
773 _ _ |a 10.1007/s11136-026-04229-5
|g Vol. 35, no. 5, p. 124
|0 PERI:(DE-600)2008960-0
|n 5
|p 124
|t Quality of life research
|v 35
|y 2026
|x 0962-9343
856 4 _ |u https://pub.dzne.de/record/285816/files/DZNE-2026-00352.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285816/files/DZNE-2026-00352.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810763
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-18
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b QUAL LIFE RES : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1180
|2 StatID
|b Current Contents - Social and Behavioral Sciences
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0130
|2 StatID
|b Social Sciences Citation Index
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
920 1 _ |0 I:(DE-2719)5000067
|k AG Michalowsky
|l Patient-Reported Outcomes and Health Economics Research
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000067
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21